Physician profile
Kelsey Cramer
NPI 1114418159
$5,395.53
in general payments reported to CMS, 2019-2025
11 companies · $2,813 in 2025
The $2,813 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.32 · 2022: $183 · 2023: $360 · 2024: $1,952 · 2025: $2,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325 · Consulting Fee: $1,700 · Travel and Lodging: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.18 |
| Consulting Fee | $1,700.00 |
| Travel and Lodging | $1,098.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,364.30 | 2023-2025 | Ofev |
| Merck Sharp & Dohme LLC | $1,318.57 | 2022-2024 | Winrevair |
| United Therapeutics Corporation | $846.06 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $491.01 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $141.33 | 2025 | |
| Philips North America LLC | $49.11 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Electromed, INC. | $43.88 | 2022-2024 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $41.26 | 2025 | Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $39.64 | 2023-2024 | |
| Glaxosmithkline, LLC. | $36.45 | 2022 | |
| Advanced Respiratory, INC | $23.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.